Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07838415

Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer

This study aims to explore whether adding an additional MRI sequence to routine liver scans can better characterize the immune microenvironment of liver cancer. We plan to prospectively enroll patients diagnosed with or suspected of having liver cancer who undergo routine MRI examinations. In addition to the standard MRI protocol, participants will receive one extra MRI sequence. We will analyze the imaging features from this additional sequence and combine them with clinical data to construct a multi-omics model. The goal is to identify imaging biomarkers that can reflect the dynamic changes of the tumor microenvironment, which may help improve the diagnosis and clinical management of liver cancer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hepatocellular Carcinoma (HCC) Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Treatment Response

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18 years or older, (b) pathologically confirmed HCC with available pathology slides, and (c) EOB-MRI including Td-dMRI within 1 month before surgery.

Exclusion criteria

  • (a) lesions smaller than 1 cm, (b) poor imaging quality, and (c) received other treatments before surgery.

Treatment and study plan

time-dependent diffusion MRI and Cest sequence

Other

Time-dependent Diffusion MRI： This is a specialized MRI technique that measures water molecule diffusion at different time intervals to probe tissue microstructural features. In tumor tissues with dense cellularity and complex architecture, water diffusion is restricted. This technique allows for the detection of changes in cell size, shape, and interstitial spaces in liver cancer, providing insights into tumor heterogeneity and microenvironment.

CEST (Chemical Exchange Saturation Transfer)： This is a molecular imaging technique based on chemical exchange. It selectively saturates exchangeable protons on specific molecules (such as proteins, peptides, or metabolites) and detects the transfer of this saturation effect to water protons, enabling indirect measurement of specific molecule concentrations in vivo. In liver cancer research, CEST can detect protein content, pH changes, and metabolic abnormalities in tumor tissues, providing functional information to assess tumor biological be

Primary outcomes

  1. The primary outcomes of this study were PFS

    Time frame: Up to 24 months after baseline MRI

    PFS was calculated from the time of receiving treatment to disease progression or death, whichever occurred first, and progression was determined based on contrast-enhanced CT or MRI scans following mRECIST criteria

Study contacts

Contact information is provided by the study sponsor or research team.

zhen li, PHD

CONTACT

[email protected]

+86 130 3717 8109

Sponsors and collaborators

Lead sponsor

Tongji Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Sep 24, 2026
Registry last updated
Sep 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.